Cargando…
Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447877/ https://www.ncbi.nlm.nih.gov/pubmed/37612802 http://dx.doi.org/10.1002/ctm2.1387 |
| _version_ | 1785094601312305152 |
|---|---|
| author | Hannawi, Suad Zhang, Rong‐Rong Abuquta, Alaa Safeldin, Linda Hassan, Aala Alamadi, Ahmad Hossain, Tasmiah Mostafa, Mohamed Ghoneim, Yasser Solo, Jennifer Zheng, Hong‐Xia Wu, Ding‐Feng Yu, Dan‐Dan Yuan, Jia‐Cheng Zhao, Di Lin, Rui Ying, Bo Qin, Cheng‐Feng |
| author_facet | Hannawi, Suad Zhang, Rong‐Rong Abuquta, Alaa Safeldin, Linda Hassan, Aala Alamadi, Ahmad Hossain, Tasmiah Mostafa, Mohamed Ghoneim, Yasser Solo, Jennifer Zheng, Hong‐Xia Wu, Ding‐Feng Yu, Dan‐Dan Yuan, Jia‐Cheng Zhao, Di Lin, Rui Ying, Bo Qin, Cheng‐Feng |
| author_sort | Hannawi, Suad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10447877 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104478772023-08-25 Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study Hannawi, Suad Zhang, Rong‐Rong Abuquta, Alaa Safeldin, Linda Hassan, Aala Alamadi, Ahmad Hossain, Tasmiah Mostafa, Mohamed Ghoneim, Yasser Solo, Jennifer Zheng, Hong‐Xia Wu, Ding‐Feng Yu, Dan‐Dan Yuan, Jia‐Cheng Zhao, Di Lin, Rui Ying, Bo Qin, Cheng‐Feng Clin Transl Med Letter to the Journal John Wiley and Sons Inc. 2023-08-23 /pmc/articles/PMC10447877/ /pubmed/37612802 http://dx.doi.org/10.1002/ctm2.1387 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Journal Hannawi, Suad Zhang, Rong‐Rong Abuquta, Alaa Safeldin, Linda Hassan, Aala Alamadi, Ahmad Hossain, Tasmiah Mostafa, Mohamed Ghoneim, Yasser Solo, Jennifer Zheng, Hong‐Xia Wu, Ding‐Feng Yu, Dan‐Dan Yuan, Jia‐Cheng Zhao, Di Lin, Rui Ying, Bo Qin, Cheng‐Feng Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study |
| title | Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study |
| title_full | Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study |
| title_fullStr | Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study |
| title_full_unstemmed | Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study |
| title_short | Safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mRNA vaccine in healthy adults: An open‐label, and single‐arm Phase 1 study |
| title_sort | safety and immunogenicity of boosting with a severe acute respiratory syndrome coronavirus 2 omicron variant mrna vaccine in healthy adults: an open‐label, and single‐arm phase 1 study |
| topic | Letter to the Journal |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447877/ https://www.ncbi.nlm.nih.gov/pubmed/37612802 http://dx.doi.org/10.1002/ctm2.1387 |
| work_keys_str_mv | AT hannawisuad safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT zhangrongrong safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT abuqutaalaa safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT safeldinlinda safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT hassanaala safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT alamadiahmad safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT hossaintasmiah safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT mostafamohamed safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT ghoneimyasser safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT solojennifer safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT zhenghongxia safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT wudingfeng safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT yudandan safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT yuanjiacheng safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT zhaodi safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT linrui safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT yingbo safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study AT qinchengfeng safetyandimmunogenicityofboostingwithasevereacuterespiratorysyndromecoronavirus2omicronvariantmrnavaccineinhealthyadultsanopenlabelandsinglearmphase1study |